Access to drug information

Therapeutic Decision Making and Evidence-Based Medicine (EBM)
📌 Globally, 30-40% of patients do not receive treatment based on current knowledge, and up to 25% of interventions are unnecessary or potentially dangerous.
📌 EBM is defined as the conscious, explicit, and judicious use of the best current evidence in making decisions about the care of individual patients.
📌 The EBM paradigm rests on three pillars: clinical evidence (research papers), healthcare professional's experience, and the patient's values and expectations.

Information Sources and Critical Analysis
🔬 Evidence often reaches professionals via congresses, expert presentations, or pharmaceutical advertising (e.g., drug representative brochures).
🚫 A critical need exists to analyze evidence critically and not rely solely on highlighted numbers or published abstracts, especially from industry sources.
💊 In the speaker's country, direct-to-consumer advertising is restricted; prescription-only medication promotion must be directed solely to authorized health professionals.
📊 A survey showed 22.2% of professionals learned about a new drug through pharmaceutical industry representatives.

Evaluating New Medications and Information Channels
✅ When a new medication is launched, the appropriate first step is reviewing technical datasheets available on regulatory agency websites (like the Spanish agency) to understand its pharmacological profile (mechanism of action, pharmacokinetics, safety profile, and approved indications).
📈 Almost 50% of 960 new drugs analyzed provided no substantial new benefit (in efficacy, effectiveness, or safety) over existing treatments.
🧪 Professionals must be prepared to critically analyze available research papers for new drugs, though time constraints often necessitate reliance on collective analysis tools.

Tools for Critical Evidence Evaluation
🛠️ Collective tools for critical evidence analysis include Drug Information Centers (CIMs), Health Technology Assessment (HTA) reports, Therapeutics Committees, independent information bulletins, and therapeutic positioning statements.
📚 Drug Information Centers analyze existing evidence based on user queries (professional, patient, or government) and produce independent reports.
📰 Information Bulletins (like the pharmacological bulletin mentioned) periodically select a relevant topic and publish analysis for subscribers, unlike CIMs which respond to specific requests.
🩺 Therapeutic Positioning Statements involve organizations and agencies making clinical management decisions based on available evidence for specific clinical situations.

Contemporary Information Challenges and Key Takeaways
📱 Modern information sources like social media (Facebook, Instagram, TikTok) spread simplified or sometimes inaccurate narratives (e.g., portraying GLP-1 agonists as purely weight-loss drugs).
🤖 Artificial Intelligence (AI) is a new tool that provides fast answers based on available web data but carries the risk of information dehumanization if not critically assessed.
🎯 Key message: When needing drug information, professionals must seek independent, reliable sources, maintain critical analysis of that evidence, and adapt to new technologies without losing critical judgment.

Key Points & Insights
➡️ Be aware that 30-40% of current patient treatments are not evidence-based, highlighting the necessity of critical evaluation.
➡️ Prioritize independent sources over industry promotions when researching new or existing medications.
➡️ Utilize collective tools like Drug Information Centers and HTA reports to manage the volume of scientific literature effectively.

📸 Video summarized with SummaryTube.com on Mar 09, 2026, 14:35 UTC